Preferences for a Long-Acting, Removable Implant for HIV Prevention among MSM and Physicians: A Discrete Choice Study

This article describes a discrete choice experiment (DCE) to estimate the preference share for the implant within a competitive context of other PrEP products (including the oral tablet, dissolvable implant, and injection) and evaluate the impact of potential implant attributes. Physicians who had prescribed oral PrEP (n=75) and MSM at risk for HIV (n=175) completed a web-based survey which prompted decision-making about PrEP product preferences. The findings from both physicians and MSM demonstrated that the removable implant could capture a meaningful portion of the preference share, making it feasible to advance in the development pipeline as an important addition to the biomedical HIV prevention toolkit. Among MSM, specifically, the cost of treatment was the most important attribute impacting product preference. Our findings inform implant developers and future payers (e.g., commercial manufacturers, insurance companies) about specific device attributes that will likely affect MSM's willingness to use and physicians' willingness to prescribe this HIV prevention strategy.PMID:36178358 | DOI:10.1089/AID.2022.0035
Source: Cell Research - Category: Cytology Authors: Source Type: research